Related Experiment Video
Updated: Jan 22, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant Cancers
Adam Stewart1, Elizabeth A Coker1,2, Sebastian Pölsterl1
1Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.
Abstract:
It is increasingly appreciated that drug response to different cancers driven by the same oncogene is different and may relate to differences in rewiring of signal transduction. We aimed to study differences in dynamic signaling changes within mutant KRAS (KRAS MT), non-small cell lung cancer (NSCLC), colorectal cancer, and pancreatic ductal adenocarcinoma (PDAC) cells. We used an antibody-based phosphoproteomic platform to study changes in 50 phosphoproteins caused by seven targeted anticancer drugs in a panel of 30 KRAS MT cell lines and cancer cells isolated from 10 patients with KRAS MT cancers. We report for the first time significant differences in dynamic signaling between colorectal cancer and NSCLC cell lines exposed to clinically relevant equimolar concentrations of the pan-PI3K inhibitor pictilisib including a lack of reduction of p-AKTser473 in colorectal cancer cell lines (P = 0.037) and lack of compensatory increase in p-MEK in NSCLC cell lines (P = 0.036). Differences in rewiring of signal transduction between tumor types driven by KRAS MT cancers exist and influence response to combination therapy using targeted agents.
Insights
Drug response varies across cancers with the same oncogene, like mutant KRAS (KRAS MT). Signaling pathway differences in colorectal cancer and non-small cell lung cancer impact targeted therapy effectiveness.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Drug response in cancers driven by the same oncogene (e.g., mutant KRAS) can differ significantly.
- These differences may stem from distinct signal transduction pathway rewiring specific to cancer types.
Purpose of the Study:
- To investigate dynamic signaling alterations in mutant KRAS (KRAS MT) non-small cell lung cancer (NSCLC), colorectal cancer, and pancreatic ductal adenocarcinoma (PDAC) cells.
- To identify differences in cellular signaling responses to targeted anticancer drugs across these KRAS MT cancer types.
Main Methods:
- Utilized an antibody-based phosphoproteomic platform to analyze 50 phosphoproteins.
- Examined responses to seven targeted anticancer drugs in 30 KRAS MT cell lines and patient-derived cancer cells.
- Assessed signaling changes upon exposure to the pan-PI3K inhibitor pictilisib.
Main Results:
- Observed significant differences in dynamic signaling between colorectal cancer and NSCLC cell lines treated with pictilisib.
- Noted a lack of p-AKTser473 reduction in colorectal cancer cells (P = 0.037).
- Identified a lack of compensatory p-MEK increase in NSCLC cells (P = 0.036).
Conclusions:
- Demonstrated that distinct signal transduction rewiring exists between different tumor types harboring KRAS MT.
- These pathway differences influence the efficacy of targeted therapy combinations.
More Related Videos
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
¹H NMR Signal Multiplicity: Splitting Patterns
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Feedback Inhibition
Self Within Cultural Contexts
Impact of Social Context on Individuals

